Prevalence of Crohn’s disease is expected to increase across most countries, although the magnitude of increase differs between countries.
By Nicola Leckenby, Epidemiologist
14 June 2016
I joined Datamonitor Healthcare as an Epidemiologist in 2015. Prior to this, I obtained an MSc (with Distinction) in Pub...
Read full bio
Crohn’s disease (CD) involves inflammation of the GI tract and most commonly affects the terminal ileum or colon. Because CD can occur in various areas of the GI tract, disease activity and severity can vary widely over time. CD is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, CD is known to involve an interaction between genetics, the immune system, and environmental factors.
Datamonitor Healthcare estimates that in 2015, there were 1.4 million diagnosed prevalent cases of Crohn’s disease (CD) across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). The prevalence of CD is expected to increase to 1.6 million in 2035 (16.9% increase). All analyzed countries are expected to experience an increase, except Japan, where the prevalent CD population is forecasted to decrease slightly. The forecasted increase in prevalent cases is due to evidence showing a consistent increase in prevalence proportions in the majority of analyzed countries. One driver of the increasing prevalence of CD is the phenomenon of compounding prevalence; a large rise in prevalence due to cumulative addition of incident cases in a chronic disease such as CD that has a young age of onset and low mortality.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>